Coartem® (artemether-lumefantrine) Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries now expected under a special global ...

As Chief Audit Officer of Novartis, Teresa and her team provide risk-based assurance and advice on key strategic topics to the Board and management, acting as a key partner to the organization to help ...

Novartis has been serving patients in Indonesia for more than 50 years, through our predecessor companies, Ciba and Sandoz.

Career Search Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search ...

The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on ...

An adverse event (or side effect) is any unwanted medical occurrence in a patient who has been given a medicinal product. This can be any unfavourable and unintended sign, symptom, or disease ...

Mi a Novartis-nál büszkék vagyunk arra, amit csinálunk, hiszen a munkánk rendkívüli hatással lehet az emberek életére. Ez nem csak egy munkahely, itt tanulni, újítani, fejlődni lehet. Segítünk abban, ...

Basel, June 25, 2025 – Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common ...

A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan on Disease Management, Treatment-Related Outcomes and Healthcare Resource Utilization for Adult Patients With Paroxysmal ...

Despite endocrine therapy (ET), the risk of recurrence for people diagnosed with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) early breast cancer (eBC) ...

Treating advanced prostate cancer demands more than clinical progress—it demands a new era of care, fueled by relentless innovation, collaborative efforts, and an unwavering push toward personalized ...

主な役割責任早期化合物の安全性評価を行いチームへ適切に評価内容を伝える。承認申請資料を作成し，当局からの照会回答を含む承認申請全般に責任をもつ。治験届に関する資料作成を行い，当局からの照会対応を含む治験届業務全般に責任をもつ。当局に対する相談について非臨床安全性 ...